Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* 70 years of age or less with body mass index (BMI) between 30 and 45 kg/m2~* Informed Consent~* Females of child-bearing potential must be using adequate contraception~Exclusion Criteria:~* Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months~* Clinically significant renal, hepatic or psychiatric disease~* Unstable thyroid disease or replacement therapy~* Nephrolithiasis~* Obesity of known genetic or endocrine origin~* Participation in a formal weight loss program or lifestyle intervention~* Glaucoma or elevated intraocular pressure~* Pregnancy or breastfeeding~* Drug or Alcohol abuse~* Smoking cessation within previous 3 months or plans to quit smoking during study~* Eating disorders within past year~* Cholelithiasis within past 6 months~* Type 2 diabetes~* Previous bariatric surgery~* Bipolar disorder or psychosis~* Steroid hormone therapy not stable for 3 months~* Systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 100 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- VI-0521 Top (Type: EXPERIMENTAL): VI-0521; high dose phentermine/topiramate
- VI-0521 Mid (Type: EXPERIMENTAL): VI-0521; mid dose phentermine/topiramate
- TPM 46 (Type: ACTIVE_COMPARATOR): mid dose topiramate
- TPM 92 (Type: ACTIVE_COMPARATOR): high dose topiramate
- PHEN 7.5 (Type: ACTIVE_COMPARATOR): mid dose phentermine
- PHEN 15 (Type: ACTIVE_COMPARATOR): high dose phentermine
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).